Citations 2
An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Donskov, Agnete Overgaard , Mackie, Sarah , Hauge, Ellen‐Margrethe , Gutiérrez, Carlos Enrique Toro , Hansen, Ib Tønder , Hemmig, Andrea Katharina , Maas, Aatke van der , Gheita, Tamer A. , Nielsen, Berit Dalsgaard , Douglas, Karen, Matteson, Eric L. , Matza, Mark , Ocampo, Vanessa , Grainger, Rebecca , Bran, Andrea, Appenzeller, Simone , Goecke, Annelise, Colmán, Nelly , Keen, Helen , Kuwana, Masataka , Gupta, Latika, Salim, Babur , Harifi, Ghita , Erraoui, M. , Ziadé, Nelly , Al-Ani, Nizar Abdulateef, Ajibade, Adeola , Frølund, Line L. , Yates, Max , Pimentel-Quiroz, Víctor R. , Lyrio, André Marun , Sandovici, Maria , Geest, Kornelis S. M. van der , Brouwer, Elisabeth , Dejaco, Christian , Keller, Kresten Krarup , Gupta, Latika , Mackie, Sarah Louise , Gheita, Tamer , Conway, Richard , Monti, Sara , Sattui, Sebastian E , Grainger, Rebecca , Keen, Helen , Kuwana, Masataka , Gupta, Latika , Ziade, Nelly , Knitza, Johannes , Pimentel-Quiroz, Victor R , Van der Geest, Kornelis S M , Dejaco, Christian , Keller, Kresten Krarup , Yates, Max , Conway, Richard , Rezuş, Elena , Dasgupta, Bhaskar , Monti, Sara , Sattui, Sebastian E. , Gromova, Margarita Aleksandrovna , Helliwell, Toby
Rheumatology | January 12, 2023 | Volume: 62 | Issue: 8 | Pages: 2797-2805
Abstract Objectives To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR >2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing >25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
Jatuworapruk, Kanon , Montgomery, Anna , Conway, Richard , Durcan, Laura, Graef, Elizabeth R. , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen , Cogo, Adriana Karina , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Malcata, Armando, Mateus, Elsa F , Schäfer, Martin , Scirè, Carlo Alberto , Sparks, Jeffrey A. , Strangfeld, Anja , Xavier, Ricardo Machado , Bhana, Suleman , Gore‐Massy, Monique , Hausmann, Jonathan S. , Sirotich, Emily , Sufka, Paul , Wallace, Zach, Machado, Pedro , Grainger, Rebecca , Ware, Anna , Gianfrancesco, Milena A , Conway, Richard , Durcan, Laura , Graef, Elizabeth R , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen J , Carmona, Loreto , Cogo, Adriana Karina , Duarte-García, Alí , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Langlois, Vincent , Lawson-Tovey, Saskia , Schaefer, Martin , Scirè, Carlo Alberto , Sigurdardottir, Valgerdur , Sparks, Jeffrey A , Xavier, Ricardo M , Bhana, Suleman , Hausmann, Jonathan S , Liew, Jean , Sirotich, Emily , Sufka, Paul , Wallace, Zachary S , Machado, Pedro M , Yazdany, Jinoos , Grainger, Rebecca , Robinson, Philip C , Strangfeld, Anja , Mateus, Elsa F , Carmona, Loreto , Duarte‐García, Alí , Lawson‐Tovey, Saskia , Liew, Jean W. , Yazdany, Jinoos , Robinson, Philip C.
ACR Open Rheumatology | August 24, 2022 | Volume: 4 | Issue: 11 | Pages: 948-953
ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID‐19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID‐19 between March 12, 2020, and October 25, 2021, were extracted from the COVID‐19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID‐19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty‐three patients with gout who developed COVID‐19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre‐COVID‐19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID‐19‐related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID‐19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID‐19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.